David Alexander Sclar, B.Pharm, Ph.D.

Professor & Chair


Midwestern University:
College of Pharmacy - Glendale 
Department of Pharmacy Practice

Cholla Hall, 201-7
19555 N. 59th Ave.
Glendale, AZ 85383 

Office: (623) 572-3521 
e-mail: dsclar@midwestern.edu 

EDUCATION

Bachelor of Pharmacy    Washington State University    1985
Doctor of Philosophy in Pharmacy    University of South Carolina     1988
Doctor of Philosophy in Business Administration    University of South Carolina     1988

RESEARCH SUMMARY

Dr. Sclar's research interests focus on issues involving pharmacoeconomics, pharmacoepidemiology, and health policy, and have been supported by over $14 million ($9.7 million as Principal Investigator) in grants from government agencies, foundations, and the biomedical/pharmaceutical industry.

BIOGRAPHICAL SUMMARY

David Alexander Sclar, B.Pharm., Ph.D. is Professor and Chair, Department of Pharmacy Practice (Division of Clinical & Experimental Therapeutics; Division of Pharmaceutical Outcomes & Policy), Midwestern University, College of Pharmacy-Glendale. Prior to joining Midwestern University, College of Pharmacy-Glendale in 2012, Dr. Sclar was Boeing Distinguished Professor of Health Policy & Administration, Professor of Pharmacotherapy, Boehringer Ingelheim Scholar in Pharmaceutical Economics, and Director, Pharmacoeconomics & Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University; a member of the Graduate Faculty, Department of Marketing (Professor of Marketing), College of Business, Washington State University; a member of the Graduate Faculty, Department of Statistics (Professor of Statistics), College of Science, Washington State University; and a member of the Graduate Faculty (Research Professor), Washington Institute for Mental Health Research & Training. Dr. Sclar is currently a member of the Graduate Faculty (Research Professor), Pharmacoeconomics & Pharmacoepidemiology Research Unit, College of Medicine and College of Pharmacy, Dalhousie University; and Queen's Trust Visiting Professor, Institute of Psychiatry, King's College School of Medicine, University of London. In 2009, Dr. Sclar served as Interim Chair, Department of Health Policy & Administration, College of Pharmacy, Washington State University. From 2000, to 2002, Dr. Sclar served as Interim Chair of faculty comprising the Department of Health Policy & Administration, and the Department of Pharmacotherapy, College of Pharmacy, Washington State University. In addition to his academic duties, Dr. Sclar served as Director of the Center for Health Services Research & Policy, and Chair of the Pharmacy & Therapeutics Committee, Wellpoint Health Plan of Washington, Inc., Inland Northwest Division, from 1993, to 1999. Dr. Sclar received a Bachelor of Pharmacy, cum laude, with a minor in Anthropology from Washington State University in 1985, a Doctor of Philosophy in Business Administration & Pharmacy from the University of South Carolina in 1988, where he was a research fellow in pharmaceutical marketing in the Center for Pharmaceutical Economics & Policy, and post-graduate training at the Cornell University Administrative Management Institute for Higher Education in 1999, the University of British Columbia Center for Management Development in 2001, and the Thunderbird School of Global Management in 2012. Dr. Sclar is listed in Who's Who in America, Who's Who in the World, and Who's Who in Medicine and Healthcare. Prior to returning to his alma mater in 1991, Dr. Sclar served on the faculty of the University of Southern California School of Pharmacy, in the Department of Pharmaceutical Economics & Policy. Dr. Sclar was the recipient of the United States Department of Health and Human Services National Quality Scholar Award in 1991, the American Society of Health-System Pharmacists Research & Education Foundation Pharmacotherapy Research Award in 1995, the American Society of Health-System Pharmacists Research & Education Foundation Pharmacy Practice Research Award in 1995, the inaugural Washington State University College of Pharmacy Faculty Excellence Award for Research in 2009, the University of Southern California School of Pharmacy Teacher of the Year Award in 1990, and 1991, and the Washington State University College of Pharmacy Teacher of the Year Award in 1998, and 2011. Dr. Sclar's research interests focus on issues involving pharmacoeconomics, pharmacoepidemiology, and health policy, and have been supported by over $14 million ($9.7 million as Principal Investigator) in grants from government agencies, foundations, and the biomedical/pharmaceutical industry.   Dr. Sclar's research and reviews (over 170 publications) have appeared in numerous journals, including, American Journal of Medicine, New England Journal of Medicine, Medical Care, PharmacoEconomics, Journal of Occupational & Environmental Medicine, Journal of Clinical Psychopharmacology, Journal of Managerial Issues, American Journal of Cardiology, American Journal of Health-Systems Pharmacy, Journal of International Medical Research, Journal of Clinical Psychiatry, International Clinical Psychopharmacology, British Medical Journal, Clinical Pediatrics, Current Therapeutic Research, Infectious Agents & Disease, Clinical Drug Investigation, Journal of Human Hypertension, CNS Drugs, Psychiatric Services, Journal of Clinical Pharmacy & Therapeutics, Antimicrobial Agents & Chemotherapy, Pharmacotherapy, International Journal of Pharmaceutical Medicine, Therapeutic Drug Monitoring, Harvard Review of Psychiatry, Journal of Cultural Diversity, Health Care for Women International, Journal of Rural Health, International Journal of Psychiatry in Medicine, General Hospital Psychiatry, Headache, Drugs in Research & Development, Diabetes Educator, American Journal of Cardiovascular Drugs, and Clinical Therapeutics, where he served as founding Section Editor for Pharmaceutical Economics & Health Policy from 1993, to 2000. Dr. Sclar has served as an advisor to the United States Presidential Commission on Health Care Reform, United States Food & Drug Administration, United States Senate Select Committee on Aging, United States Veterans Administration, Australia Ministry of Health, Canada Ministry of Health, Republic of China Bureau of Drugs & Biologicals, New Zealand Ministry of Health, Republic of South Africa Ministry of Health, United Kingdom National Health Service, World Health Organization, 3M, Allergan, Alza, Amgen, AstraZeneca, Aventis, Axcan, Baxter Bioscience, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Gambro, Genentech, Genzyme, GlaxoSmithKline, Jazz, Johnson & Johnson, Merck, Mylan, Novartis, Optimer, Pfizer, Teva, and Wyeth.